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their relative importance weights (%) were: robustness of clinical evidence (31%);
robustness of CE estimates (25%); availability of alternative treatments (8%); incre-
mental efficacy (8%); relative safety (7%); ease of adoption (7%); incremental impact
on QOL (5%); budget impact (4%); unmet need (3%); size of population (1%). The
attribute levels and relative value for a positive reimbursement recommendation
(0-1) for the most important attribute, robustness of clinical evidence, were: ‘end-
points and/or comparators not relevant to payers’ (0); ‘weak intermediate clinical
endpoints, indirect comparisons needed’ (0.25); ‘all clinical endpoints and compar-
ators relevant for NHS’ (1). The estimates of the probability of a favorable reim-
bursement recommendation for the hypothetical products included in the post-
workshop questionnaire using the logistic regression model had 71% positive
predictive value and 91% negative predictive value when compared to participant
decisions for these hypothetical products provided in responses to the post-work-
shop questionnaire. CONCLUSIONS: An MCDA process can provide both a qualita-
tive understanding and quantitative estimates of the relative importance, attribute
levels, and value scales of different product attributes that influence a positive
reimbursement decision in the UK.
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OBJECTIVES: The meaning of ‘value’ and the criteria for judging it are increasingly
being debated in countries with established reimbursement processes using
Health Technology Assessment (HTA). The objective of this study is to determine
the criteria used in decision-making to determine value in OECD countries’ deci-
sion-making processes using health economic analysis (HEA).METHODS:A review
of reimbursement agencies’ websites, relevant literature and contact with individ-
ual agencies identified the criteria used to determine value for medicines in pro-
cesses using HEA. Countries are categorised by how HEA is used in decision-mak-
ing processes, nature of the cost-effectiveness threshold range (explicit, implicit,
no threshold), threshold range where identified and the use of such evidence
alongside other decision-making criteria (burden of disease, severity, innovation
and others). Details of the judgments reported with respect to the criteria in doc-
uments justifying the decision are examined. RESULTS: Twenty-four OECD coun-
tries use formal HTA of which 17 require HEA in submissions for certain medicines.
Cost-effectiveness thresholds are identified in nine countries, explicitly stated in
three. Implicit threshold ranges are identified in four (based on past decisions),
whilst in two implicit willingness-to-pay thresholds are used for decision-making.
Use of HEA is always accompanied by other criteria (severity, need, burden of
disease, end of life, innovation, amongst others). Some countries use cost-effec-
tiveness thresholds central to their decision-making, some report them equally
amongst other criteria, whilst in others it is unclear how such criteria is judged.
Details relating to the judgement of criteria used in appraisals are sparse.
CONCLUSIONS: Multiple criteria are common in countries using HEA, although
some are country specific. Reporting of these criteria and their respective use and
interpretation alongside the cost-effectiveness threshold range suggests variation
in the meaning of value. Multi-criteria decision analysis could provide clarity in the
justification of the reimbursement decision and the meaning of value.
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OBJECTIVES: During 2011-2012 significant price cuts were implemented in various
markets in the European Union. These price cuts have introduced new pricing
dynamics affecting reference pricing and intra-EU parallel export of expensive
drugs. METHODS: To understand new pricing dynamics in the big five EU (UK,
France, Germany, Italy and Spain) we analyzed the trend in pricing for branded and
biosimilar GM-CSF products. Prices were analyzed for percentage discount com-
pared to branded GM-CSF product and relative price levels in five selected markets.
Recent reimbursement policy changes, and price cuts were also analyzed.
RESULTS: The 2012 prices for GM-CSF products show significant variation across
UK, France, Germany, Italy and Spain. The prices for GM-CSF products were dra-
matically lower in Spain and UK compared to France, Germany and Italy. For ex-
ample, for branded GM-CSF product prices in Spain were 80% lower than prices in
the UK. Similarly, the prices for biosimilar GM-CSF products were 72% lower in
Spain than in the UK. The percentage price discount for biosimilar products versus
branded product also shows large variation in big five EU markets. For example,
Spain and UK prices were almost at parity while the prices in France, Germany and
Italy showed 12%, 31% and 26% discount, respectively.CONCLUSIONS: Recent pric-
ing reforms have significantly changed the pricing dynamic across big five EU
markets. Case study of GM-CSF products illustrates wide variation in pricing for
branded and biosimilar products.
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OBJECTIVES: In France, reimbursement of drugs is based on the therapeutic value
of drugs (SMR level for each indication) as assessed by HAS, going from “insuffi-
cient” (no reimbursement at all) to “weak” (15% reimbursement), “moderate” (30%)
and “important” (65%). HAS and manufacturer have the right to ask for re-assess-
ment anytime after the initial reimbursement listing; in all cases, a relisting pro-
cess is compulsory every 5 years. We analyzed HAS’s reassessment and relisting
activity over the year 2011, based on the hypothesis that the Mediator safety “af-
fair” would have impacted the process. METHODS: We considered all complete
procedures for relisting, re-assessments and class reviews and focused on drugs for
which a HAS advice was published between Jan and Dec 2011. We compared pre-
vious and new SMR levels for each indication. RESULTS: Twenty-six drugs have
gone the relisting process, corresponding to 33 different indications, out of which
31 cases were analyzable: HAS modified 14 SMRs while 17 SMRs remained un-
changed. Almost 50% (6/13) of SMR initially rated as “important” were changed to
“insufficient” (4) or “moderate” (2). All initially insufficient SMR (8) were confirmed.
19 drugs have gone through re-assessment process, corresponding to 24 SMRs/
indication, out of each only 21 were analyzable: 10 SMRs have been modified (only
2 increased and the rest lowered) and 11 unchanged. In 8 of these cases, the man-
ufacturer had asked for the re-assessment. 6 full therapeutic classes have been
reviewed in 2011, including Alzheimer’s and antipschychotics, resulting in a har-
monization and a decrease of the SMR levels. CONCLUSIONS: Manufacturers
should now ensure that reassessment and relisting dossiers in France incorporate
as much of relevant clinical, safety and real-life information as possible in order to
maintain the reimbursement level.
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OBJECTIVES: Every day health care decison makers on the national, regional and
local level face the challenge of making complex funding decisions. The complexity
in drug funding decisions comes from balancing quantitative criteria such as clin-
ical evidence and qualitative criteria such as personal experience of decison mak-
ers. This systematic literature review reflects the research status on applied criteria
in drug funding decisions. METHODS: Relevant literature has been identified by
using a systematic database search process as described by Tranfield, Denyer &
Smart (2003) via EBSCO and Science Direct. Topic relevant search terms were ap-
plied which resulted in 412 papers. Detailed screening of the paper abstracts with
application of inclusion criteria reduced the number of relevant papers down to 20.
Following this, information from those 20 papers has been analysed and compared
to practitioner experience. RESULTS: The most discussed criteria with influence on
drug funding decisions were the importance and use of economic evaluations and
the importance of political and social factors for the decision process. Both topics
were discussed in six studies (30% each). More than half of the studies (14 out of 20)
showed evidence that drug funding decisions are decided not only by quantitative
criteria, but also decided by qualitative criteria. Another finding was a geographical
research prioritization. The most discussed country in the relevant studies was the
UK (23%) followed by Canada (15%), the Netherlands (13%), Australia, France and
the USA (each 10%). CONCLUSIONS: Relevant research literature shows the exis-
tence of quantitative criteria influencing drug funding decision-making but also
the use of qualitative criteria seems to be proved. Although this is seldom docu-
mented publicly, qualitative criteria are shown to have an impact on drug funding
decisions. Further research work is necessary to extend knowledge about the im-
pact of qualitative criteria in drug funding decision-making.
PHP123
IMPORTANCE OF HEALTH-RELATED QUALITY OF LIFE AS AN ENDPOINT IN
BENEFIT ASSESSMENT ACCORDING TO THE GERMAN AMNOG
Koester C1, Kossmann B1, Boehm K1, Wasem J2, Aidelsburger P1
1CAREM GmbH, Sauerlach, Bavaria, Germany, 2University Duisburg-Essen, Essen, Germany
OBJECTIVES:Health-related quality of life (HRQoL) might be one important patient
reported endpoint (PRO) in determining the additional benefit of pharmaceuticals
recently evaluated according to the newly established German law for reforming
the market for pharmaceuticals (AMNOG). A comparative analysis is performed to
gain insight how HRQoL was implemented in the benefit dossier by the pharma-
ceutical manufacturer on the one hand and how it was assessed in the benefit
assessment by the Institute for Quality and Efficiency in Health Care (IQWiG) on the
other hand. METHODS: We reviewed 23 published benefit dossiers and the corre-
sponding benefit assessments, which the IQWiG performed since the implemen-
tation of the AMNOG in 2011. Corresponding statements concerning HRQoL in
benefit dossiers and benefit assessment were faced narrative. RESULTS: Eighteen
benefit dossiers reported HRQoL and a number of validated instruments were used,
which were generally accepted by the IQWiG if not for major mistakes in the benefit
dossiers (for example the use of another appropriate comparator). Overall, the
pharmaceutical manufacturers have difficulties to clearly prove an additional ben-
efit due to HRQoL because the used studies do not contain data on this endpoint or
the results are statistical non-significant. The IQWiG draws a similar conclusion as
the pharmaceutical manufacturers and attests none of the benefit dossiers an
additional benefit due to HRQoL. A common methodological problem reported in
the benefit assessments is for example a low response rate so that the data has high
bias potential. CONCLUSIONS: None of the published benefit assessments state an
additional benefit in HRQoL although this is an important PRO and the pharmaceu-
tical manufacturers presented a range of accepted validated instruments to assess
it. Dealing with data uncertainties concerning the HRQoL has to be accomplished in
the future of the benefit assessment.
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